Evaluation Of Association Between Diabetes Related Quality Measure Achievement And Diabetes Complications In A Medicare Advantage Population

Abstract

regulatory reviews faster than the EMA while beginning regulatory review first in each case. Three of the four regulatory decisions in which the FDA was slower were outliers in terms of approval time. Additionally, when looking at the median, the FDA approved these moieties 77 days faster than the EMA while Downing's findings only showed a 44-day differential. This was expected because the analysis included the EC decision takes about 2 months on average. ConClusions: After updating the data, restricting it to a particular subset of diabetes treatments, and altering the EMA regulatory endpoint, Downing et al's findings not only still hold true, but become even more pronounced.